After Hours
|
||||
|
|
|
|
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-16.57/-2.14
|
|
Enterprise Value
1.13B
|
| Balance Sheet |
|
Book Value Per Share
4.73
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
200.00K
|
|
Operating Revenue Per Share
0.04
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quotes are at least 15-min delayed:2025/11/18 19:01 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function. |

79.14 
